Executive Summary:
This notification, No. 41/2020-Customs, issued by the Ministry of Finance, Department of Revenue, makes further amendments to Notification No. 16/2017-Customs, dated April 20, 2017. The amendments involve substitutions in the Table of the original notification, modifying entries in columns 3 and 4 with corresponding entries in columns 2 and 3, as specified in the attached table. It was issued on October 29, 2020.
Key Points / Main Content:
* **Amendment Authority:** The notification is issued under subsection 1 of section 25 of the Customs Act, 1962.
* **Amendment Details:**
* The notification amends the Table within Notification No. 16/2017-Customs.
* It substitutes entries in columns 3 and 4 of the original table with new entries.
* The substitutions are detailed in the provided Table.
* **Table Substitutions:** The following substitutions are made (Column 1 represents the serial number in the original table):
* 17: "Win for Patients Cancer Care Umaang Novartis Healthcare Private Limited"
* 18: "Win for Patients Cancer Care Umaang Novartis Healthcare Private Limited"
* 19: "Win for Patients Cancer Care Umaang Novartis Healthcare Private Limited"
* 20: "Win for Patients Cancer Care Umaang Sandoz India Private Limited"
* 21: "Win for Patients Cancer Care Umaang Novartis Healthcare Private Limited"
* 22: "Win for Patients Cancer Care Umaang Novartis Healthcare Private Limited"
* 43: "Sutent Patient Assistance Programme STAR Pfizer Products India Private Limited"
* 44: "Crizalk Patient Assistance Programme STAR Pfizer Products India Private Limited"
* 45: "Inlyta Patient Assistance Programme STAR Pfizer Products India Private Limited"
* 46: "Palbace Patient Assistance Programme PRERNA Pfizer Products India Private Limited"
* 47: "Enbrel Patient Assistance Programme Pfizer Limited"
* 48: "Xeljanz Patient Assistance Programme Pfizer Limited"
* 49: "Genotropin Patient Assistance Programme Pfizer Products India Private Limited"
* 50: "Atgam Patient Assistance Programme Pfizer Products India Private Limited"
* 51: "Aromasin Patient Assistance Programme Pfizer Products India Private Limited"
* 52: "Campto Patient Assistance Programme Pfizer Products India Private Limited"
Impact Analysis:
* **Central Government:**
* *Impact:* The Central Government is the issuing authority and responsible for the amendments to the Customs Act.
* *Action Required:* Ensure compliance with the Customs Act, 1962 and the amended notification.
* **Ministry of Finance (Department of Revenue):**
* *Impact:* Responsible for implementing and overseeing the changes to customs duties and regulations.
* *Action Required:* Update relevant systems and procedures to reflect the changes in the notification.
* **Customs Officials:**
* *Impact:* Must enforce the amended regulations and ensure accurate application of the new entries.
* *Action Required:* Familiarize themselves with the changes to correctly assess and collect customs duties.
* **Importers/Exporters:**
* *Impact:* May experience changes in customs duties or procedures related to the listed products.
* *Action Required:* Review the changes to understand their impact on import/export activities and ensure compliance.
* **Pharmaceutical Companies (Novartis, Sandoz, Pfizer):**
* *Impact:* Changes in customs duties or procedures related to their patient assistance programs.
* *Action Required:* Review the changes to understand their impact on the listed patient assistance programs and ensure compliance.
Key Entities Referenced
Ministry of Finance: The ministry responsible for the notification.
Department of Revenue: A department within the Ministry of Finance.
Customs Act, 1962: The primary legislation related to customs duties and regulations in India.
New Delhi: The location of the notification, likely where the Ministry of Finance is located in Delhi, India.
G.S.R. 683 E: A reference number for the notification.
No. 162017Customs: Original Notification being amended.
No. 832017Customs: Notification that last amended the original notification.
Novartis Healthcare Private Limited: A pharmaceutical company providing cancer care.
रजिस्ट्री स.ं डी.एल.- 33004/99 REGD. No. D. L.-33004/99
सी.जी.-डी.एल.-अ.-29102020-222811
xxxGIDHxxx
CG-DL-E-29102020-222811
xxxGIDExxx
असाधारण
EXTRAORDINARY
भाग II—खण् ड 3—उप-खण्ड (i)
PART II—Section 3—Sub-section (i)
प्राजधकार स ेप्रकाजित
PUBLISHED BY AUTHORITY
स.ं 559] नई दिल्ली, बृहस्ट्प जतिार, अक्त बू र 29, 2020/कार्तकि 7, 1942
No. 559] NEW DELHI, THURSDAY, OCTOBER 29, 2020/KARTIKA 7, 1942
जित्त मत्रं ालय
(रािस्ट्ि जिभाग)
अजधसचू ना
नई दिल्ली, 29 अक्त ूबर, 2020
सख्ं य ा 41/2020-सीमािल्ु क
सा.का.जन. 683(अ).—सीमा िुल्क अजधजनयम, 1962 (1962 का 52) की धारा 25 की उपधारा (1) के तहत
प्रित्त िजियों का प्रयोग करत े हुए, केन्द्र सरकार, इस बात से संतुष्ट होते हुए दक ऐसा करना िनजहत म ें आिश्यक ह,ै
एतिद्वारा भारत सरकार जित्त मंत्रालय (रािस्ट्ि जिभाग) की अजधसूचना सं. 16/2017-सीमािुल्क दिनााँक 20 अप्रलै ,
2017, जिस े सा.का.जन. 394 (अ) दिनााँक 20 अप्रलै , 2017 के तहत भारत के रािपत्र, असाधारण, के भाग II खण्ड 3,
उपखण्ड (i) में प्रकाजित दकया गया था, म ेंऔर आगे भी जनम्नजलजखत संिोधन करती ह,ै यथााः-
उि अजधसूचना म,ें सारणी में, नीच े िी गयी सारणी के कॉलम (1) की क्रम संख्याओं के कॉलम (3) और कॉलम
(4) की प्रजिजष्टयों के स्ट्थान पर नीचे िी गयी सारणी के कॉलम (2) और कॉलम (3) की प्रजिजष्टयों को प्रजतस्ट्थाजपत दकया
िाएगा, यथााः-
5272 GI/2020 (1)2 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(i)]
सारणी
(1) (2) (3)
17. “जिन फॉर पेिेंट-कैंसर केयर/उमंग नोिार्टिस हल्ै थकेयर प्राइिेट जलजमटेड
18. जिन फॉर पेिेंट-कैंसर केयर/उमगं नोिार्टिस हल्ै थकेयर प्राइिेट जलजमटेड
19. जिन फॉर पेिेंट-कैंसर केयर/उमगं नोिार्टिस हल्ै थकेयर प्राइिेट जलजमटेड
20. जिन फॉर पेिेंट-कैंसर केयर/उमगं सेंडोि इजण्डया प्राइिेट जलजमटेड
21. जिन फॉर पेिेंट-कैंसर केयर/उमगं नोिार्टिस हल्ै थकेयर प्राइिेट जलजमटेड
22. जिन फॉर पेिेंट-कैंसर केयर/उमगं नोिार्टिस हल्ै थकेयर प्राइिेट जलजमटेड
43. सुटेंट पेिेंट अजससटेंस प्रोग्राम-स्ट् टार फाइिर प्रोडक््स इजण्डया प्राइिेट जलजमटेड
44. दक्रिाक पेिेंट अजससटेंस प्रोग्राम-स्ट् टार फाइिर प्रोडक््स इजण्डया प्राइिेट जलजमटेड
45. इन्द्लाईटा पेिेंट अजससटेंस प्रोग्राम-स्ट् टार फाइिर प्रोडक््स इजण्डया प्राइिेट जलजमटेड
46. पलबेस पेिेंट अजससटेंस प्रोग्राम-प्रेरणा फाइिर प्रोडक््स इजण्डया प्राइिेट जलजमटेड
47. एनब्रेल पेिेंट अजससटेंस प्रोग्राम फाइिर जलजमटेड
48. िेलिांि पेिेंट अजससटेंस प्रोग्राम फाइिर जलजमटेड
49. िेनोरोजपन पेिेंट अजससटेंस प्रोग्राम फाइिर प्रोडक््स इजण्डया प्राइिेट जलजमटेड
50. एटगम पेिेंट अजससटेंस प्रोग्राम फाइिर प्रोडक््स इजण्डया प्राइिेट जलजमटेड
51. एरोमाजसन पेिेंट अजससटेंस प्रोग्राम फाइिर प्रोडक््स इजण्डया प्राइिेट जलजमटेड
52. केंम्टो पेिेंट अजससटेंस प्रोग्राम फाइिर प्रोडक््स इजण्डया प्राइिेट जलजमटेड”.
[फा.सं. 332/24/2010-टीआरयू (पाटि III)]
गौरि ससंह, उप सजचि
नोटाः प्रधान अजधसूचना स.ं 16/2017-सीमा िुल्क दिनांक 20 अप्रलै , 2017 को सा.का.जन. 394 (अ) दिनांक 20 अप्रलै ,
2017 के तहत भारत के रािपत्र, असाधारण, के भाग II , खण्ड 3 उपखण्ड (i) म ें प्रकाजित दकया गया था और इसम ें
अंजतम बार अजधसूचना सं. 83/2017-सीमािुल्क, दिनांक 31 अक्टूबर, 2017, सा.का.जन. 1356 (अ), दिनांक 31
अक्टूबर, 2017 के तहत भारत के रािपत्र, असाधारण, के भाग II , खण्ड 3 उपखण्ड (i) में प्रकाजित दकया गया था, के
द्वारा संिोधन दकया गया ह।ै
MINISTRY OF FINANCE
(Department of Revenue)
NOTIFICATION
New Delhi, the 29th October, 2020
No. 41/2020-Customs
G.S.R. 683 (E).—In exercise of the powers conferred by sub-section (1) of section 25 of the Customs
Act,1962 (52 of 1962), the Central Government, on being satisfied that it is necessary in the public interest so to
do, hereby makes the following further amendments in the notification of the Government of India, in the
Ministry of Finance (Department of Revenue), No. 16/2017-Customs, dated the 20th April, 2017, published in the
Gazette of India, Extraordinary, Part II, Section 3, Sub-section (i), vide number G.S.R.394 (E), dated the 20th
April, 2017, namely:-[भाग II—खण् ड 3(i)] भारत का रािपत्र : असाधारण 3
In the said notification, in the Table, for the entries in column (3) and column (4) at the serial numbers
given in column (1) of the Table below, the corresponding entries at column (2) and column (3) of the Table below
shall be substituted, namely:-
TABLE
(1) (2) (3)
17. “Win for Patients- Cancer Care/ Umaang Novartis Healthcare Private Limited
18. Win for Patients- Cancer Care/ Umaang Novartis Healthcare Private Limited
19. Win for Patients- Cancer Care/ Umaang Novartis Healthcare Private Limited
20. Win for Patients- Cancer Care/ Umaang Sandoz India Private Limited
21. Win for Patients- Cancer Care/ Umaang Novartis Healthcare Private Limited
22. Win for Patients- Cancer Care/ Umaang Novartis Healthcare Private Limited
43. Sutent Patient Assistance Programme -STAR Pfizer Products India Private Limited
44. Crizalk Patient Assistance Programme -STAR Pfizer Products India Private Limited
45. Inlyta Patient Assistance Programme -STAR Pfizer Products India Private Limited
46. Palbace Patient Assistance Programme -PRERNA Pfizer Products India Private Limited
47. Enbrel Patient Assistance Programme Pfizer Limited
48. Xeljanz Patient Assistance Programme Pfizer Limited
49. Genotropin Patient Assistance Programme Pfizer Products India Private Limited
50. Atgam Patient Assistance Programme Pfizer Products India Private Limited
51. Aromasin Patient Assistance Programme Pfizer Products India Private Limited
52. Campto Patient Assistance Programme Pfizer Products India Private Limited”.
[F. No. 332/24/2010-TRU (Pt.III)]
GAURAV SINGH, Dy. Secy.
Note: The principal notification No. 16/2017-Customs, dated the 20th April, 2017 was published in the Gazette of
India, Extraordinary, Part II, Section 3, Sub-section (i) vide number G.S.R.394 (E), dated the 20th April, 2017,
and was last amended by notification No. 83/2017-Customs, dated the 31st October, 2017 published in the
Gazette of India, Extraordinary, Part II, Section 3, Sub-section (i) vide number G.S.R. 1356 (E), dated the 31st
October, 2017.
Uploaded by Dte. of Printing at Government of India Press, Ring Road, Mayapuri, New Delhi-110064
and Published by the Controller of Publications, Delhi-110054.